What Current Research and Regulatory Reviews Say About GLP-1 Drugs and Mental Health
Last updated: May 2026 | Covers: Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus | Read time: ~10 min
If you are experiencing thoughts of suicide or self-harm, please contact the 988 Suicide and Crisis Lifeline by calling or texting 988. You can also reach the Crisis Text Line by texting HOME to 741741. If you are in immediate danger, call 911 or go to your nearest emergency room.
As GLP-1 medications have moved from specialist diabetes practices into mainstream prescribing — and into the hands of millions of patients using them primarily for weight management — questions about their effects on mood and mental health have followed close behind. Some patients taking Ozempic, Wegovy, Mounjaro, and related drugs have reported depression, anxiety, and in some cases suicidal thoughts during their treatment. Those reports have attracted regulatory attention from the FDA, the European Medicines Agency, and the World Health Organization, and they continue to generate research.
The current state of the evidence is genuinely mixed, and understanding it requires holding two things simultaneously: on one hand, multiple large studies and two major regulatory reviews have found no confirmed causal link between GLP-1 drugs and depression or suicide risk. On the other hand, a meaningful subset of patients have reported real psychiatric experiences during GLP-1 treatment, the biological plausibility of a mood-related effect is not zero given these drugs’ central nervous system activity, and surveillance remains ongoing. This article works through the evidence on both sides, explains why the research is difficult to interpret, and addresses what patients and clinicians should watch for.
Does Ozempic Cause Depression or Suicidal Thoughts? What the Evidence Shows
The direct answer, based on what regulators and researchers have concluded to date, is that no causal link between GLP-1 drugs and depression or suicidal ideation has been established. Both the FDA and the European Medicines Agency have conducted formal reviews of the available data and reached that conclusion. That matters, and it should be clearly stated.
At the same time, the absence of an established causal link is not the same as evidence that no effect exists. It reflects the limits of the data currently available — data that is largely observational, subject to significant confounding, and still accumulating. The regulatory position is appropriately cautious in both directions: neither concluding that the drugs cause psychiatric harm, nor concluding that they definitely do not. Ongoing post-market surveillance reflects that continued uncertainty.
The FDA’s January 2026 review of available data did not find evidence of increased risk of suicide, depression, psychosis, irritability, or anxiety associated with GLP-1 drugs. However, the agency continues monitoring adverse event data and has not issued a definitive safety determination on this question.
Why Mental Health Questions Arose for This Drug Class
Concern about psychiatric effects in GLP-1 drug users did not emerge arbitrarily. It arose from a specific regulatory and clinical history, and understanding that context explains why the question remains actively monitored even without a confirmed causal finding.
Adverse Event Reports in FAERS and International Databases
Post-market adverse event reporting systems in multiple countries, including the FDA’s FAERS database and equivalent systems operated by the EMA and WHO, began accumulating reports of depression, suicidal ideation, and mood disturbances in GLP-1 drug users as prescribing expanded. Adverse event reports do not prove causation — they are signal detection tools, not causal analyses — but when reports accumulate in consistent patterns across multiple independent databases, they generate the kind of regulatory signal that requires formal investigation. The EMA initiated a formal psychiatric safety review of GLP-1 drugs in 2023, which subsequently concluded without identifying a confirmed causal link but recommended continued monitoring.
Historical Precedent With Other Weight-Loss Medications
Regulatory caution around psychiatric effects in weight-loss drugs is not new. Rimonabant, a cannabinoid receptor antagonist approved in Europe for obesity management, was withdrawn from the market in 2008 after serious psychiatric adverse events including depression and suicidal ideation emerged in post-market experience. Sibutramine, another weight-loss agent, also had psychiatric adverse events in its safety profile. This history means that regulators and clinicians approach the psychiatric safety of new weight-loss drugs with a heightened baseline of attention, and that the question of whether GLP-1 drugs could produce similar effects was always likely to be scrutinized carefully regardless of the initial clinical trial data.
The Drug’s Central Nervous System Activity
GLP-1 receptors are not confined to the pancreas and gastrointestinal tract. They are expressed in multiple regions of the brain, including areas involved in mood regulation, appetite, reward processing, and stress response. That central expression is part of why GLP-1 drugs suppress appetite and alter food-related behavior. It is also why the biological plausibility of a mood-related effect — in either direction — is not zero. The same central GLP-1 signaling that suppresses appetite and may reduce compulsive eating behavior could, in theory, affect other aspects of emotional regulation. Whether it does, and in which direction, remains an open scientific question.
What the Research Shows: A Mixed Picture
Published research on GLP-1 drugs and psychiatric outcomes has produced results that point in different directions, and the methodological limitations of the available studies make it difficult to draw firm conclusions. Both sides of the research picture are worth understanding.
Studies Raising Concerns
An analysis using World Health Organization adverse event data identified a disproportionate reporting signal for suicidal ideation among semaglutide users compared to certain other diabetes medications. The signal appeared more pronounced in patients who were also taking antidepressants, which may suggest an interaction effect or may reflect confounding by indication — patients on antidepressants are already more likely to be at elevated baseline psychiatric risk. The study’s authors were appropriately cautious about its implications, noting that the overall number of events was small and that observational adverse event data cannot establish causation. However, the finding was consistent enough to warrant formal regulatory review and continued monitoring.
A separate analysis of FAERS data found reports of self-injurious behavior and suicidal ideation in GLP-1 users at rates that researchers described as worthy of attention. As with all FAERS-based analyses, the absolute event counts and the limitations of voluntary reporting systems constrain what can be concluded — but the signal contributed to the regulatory reviews that followed.
Studies Showing No Increased Risk or Possible Benefit
Multiple large-scale population studies have reached quite different conclusions. Several analyses involving millions of patients found that GLP-1 drug users had lower rates of depression, anxiety, and suicidal ideation compared to people using other diabetes or weight-loss treatments. These findings are not entirely surprising: significant weight loss, improved glycemic control, reduced physical burden from obesity-related conditions, and enhanced quality of life are all associated with improved mood outcomes. If GLP-1 drugs are producing genuine improvements in metabolic health and physical function, some degree of secondary mental health benefit might be expected in the population as a whole.
A 2024 analysis published in Nature Medicine examined psychiatric outcomes in a large cohort of GLP-1 users and found no increased risk of depression or suicidal ideation — and in some subgroups, a statistically significant reduction in psychiatric event rates. The study’s authors noted that any psychiatric benefit observed may be attributable to weight loss and metabolic improvement rather than a direct psychiatric effect of GLP-1 receptor activation, but the findings are nonetheless inconsistent with a hypothesis of widespread psychiatric harm.
Why This Research Is Particularly Difficult to Interpret
The conflicting findings in the GLP-1 psychiatric literature are not simply a reflection of poor-quality studies. They reflect genuine methodological challenges that make this question harder to study than most pharmaceutical safety questions. Understanding those challenges is important for reading any claims in this area critically.
Confounding by Indication
The patients being prescribed GLP-1 drugs are not a random sample of the general population. They are predominantly people with Type 2 diabetes, obesity, or both — conditions that are independently and strongly associated with higher rates of depression, anxiety, and suicidal ideation. When a study observes that GLP-1 users have higher rates of depression than people not taking GLP-1 drugs, it is nearly impossible to determine how much of that difference reflects the drug’s effects versus the baseline psychiatric burden that comes with having the underlying conditions for which the drug was prescribed. Researchers use statistical adjustment techniques to try to account for this confounding, but those adjustments are imperfect and require assumptions that may not hold in every dataset.
The Directionality Problem
GLP-1 drugs produce significant changes in appetite, body weight, eating behavior, and metabolic function. All of these changes can independently affect mood. A patient who loses 40 pounds, improves their HbA1c, and no longer needs insulin injections may experience meaningfully improved mood — not because of any direct psychiatric drug effect, but because their health and quality of life have genuinely improved. Conversely, a patient who experiences persistent nausea, significant dietary restriction, social isolation around food, or rapid loss of the emotional comfort associated with eating may experience worsening mood for reasons that have nothing to do with direct neurological GLP-1 receptor effects. Disentangling these pathways from a direct drug effect on brain chemistry is methodologically very difficult.
Rapid Changes in Prescribing Patterns
The population of GLP-1 drug users has changed dramatically and rapidly over the past several years as the drugs have expanded from specialist diabetes management into primary care weight management. The psychiatric risk profile of a patient prescribed Ozempic for Type 2 diabetes by an endocrinologist is likely different from the psychiatric risk profile of a patient prescribed Wegovy for weight loss through a telehealth platform. Studies conducted in earlier prescribing periods may not reflect the risk profile of the current, much larger and more diverse patient population.
What Regulators Concluded
In January 2026, the FDA completed its formal review of available data on GLP-1 drugs and psychiatric risks. The agency concluded that the available evidence did not demonstrate an increased risk of suicide, depression, psychosis, irritability, or anxiety associated with semaglutide and other GLP-1 medications. The FDA did not close out its monitoring of this question — post-market surveillance of psychiatric adverse events continues — but the January 2026 statement represents the agency’s current formal position. For context on how the FDA’s regulatory process around GLP-1 drug safety has evolved, including the full label change history for Ozempic, see our FDA warning labels and regulatory history page.
The European Medicines Agency conducted a similar review in 2023 following reports of suicidal ideation in GLP-1 users in multiple countries. The EMA’s review, which examined data from clinical trials, observational studies, and the EudraVigilance adverse event database, also concluded that available data did not confirm a causal association between GLP-1 drugs and suicide or self-harm. However, the agency simultaneously noted that the review was conducted against the backdrop of limited long-term psychiatric safety data, and that continued pharmacovigilance was warranted.
The significance of both reviews for patients is straightforward: neither major regulatory agency has concluded that these drugs cause psychiatric harm. Their continued monitoring reflects appropriate scientific caution rather than an expectation that harm will be confirmed.
Mood, Appetite, and What Patients Call “Ozempic Personality”
Alongside formal psychiatric safety concerns, a separate and somewhat different set of observations has attracted significant public discussion: reports from patients and clinicians that GLP-1 drugs appear to change not just appetite, but the emotional and psychological relationship with food, and in some cases with other reward-driven behaviors.
Patients have described experiences including diminished food cravings, reduced interest in alcohol, changes in compulsive or comfort-eating behaviors, and in some cases a broader reduction in impulsive behavior. These experiences have been colloquially described as “Ozempic personality” in popular media coverage, though the term is not a medical one and does not have a precise scientific definition.
What the research suggests is that GLP-1 receptors expressed in the brain’s reward circuitry — including the nucleus accumbens and other dopaminergic regions involved in motivation, habit, and craving — may mediate some of these behavioral changes. Whether this constitutes a psychiatric effect, a metabolic effect that secondarily influences behavior, or simply a reduction in appetite that patients experience as a change in their relationship with food is a question the science has not yet resolved. What is clear is that the changes some patients notice are real, and they reflect the drug’s activity in the central nervous system rather than simply its effects on the gut.
For a broader discussion of the unusual and less commonly discussed effects that some GLP-1 users have reported — including changes in addictive behavior, compulsive behavior, and reward processing — see our unusual GLP-1 side effects page.
GLP-1 Drugs and the Brain: Emerging Research Directions
Beyond the psychiatric safety question, researchers are increasingly interested in whether GLP-1 receptor agonists might have therapeutic applications in neurological and psychiatric conditions. This research is early-stage and exploratory — none of the findings below support any current clinical recommendation — but they reflect the extent to which GLP-1 receptor biology in the central nervous system is an active frontier in biomedical research.
Studies examining the potential of GLP-1 drugs in Alzheimer’s disease have attracted particular attention. GLP-1 receptors expressed in hippocampal neurons appear to influence neuroplasticity and inflammatory signaling in ways that may be relevant to neurodegeneration. Early clinical trial data has been mixed but sufficiently interesting to justify continued investigation. Similarly, the reduction in alcohol and substance use that some patients report during GLP-1 therapy has generated interest in whether these drugs might have utility in addiction medicine. Neither area has produced findings that would currently support clinical use of GLP-1 drugs for these purposes, but both are active research programs. For coverage of the Alzheimer’s and neurological research, see our GLP-1 research page.
Symptoms Patients and Caregivers Should Monitor
The absence of a confirmed causal link between GLP-1 drugs and psychiatric harm does not mean that patients taking these medications should ignore mood changes. Psychiatric symptoms can occur during GLP-1 treatment for reasons that may or may not be related to the medication, and any significant mood change warrants clinical attention regardless of its cause. Patients and caregivers should be alert to the following:
- Persistent sadness, hopelessness, or emotional emptiness that is new or worsening
- Loss of interest or pleasure in activities that were previously enjoyable
- Significant changes in sleep — either difficulty sleeping or sleeping much more than usual
- Changes in appetite or weight that feel distressing rather than therapeutic
- Unusual irritability, agitation, or emotional lability
- Difficulty concentrating or a sense of mental fog that is more pronounced than prior to starting the medication
- Fatigue that is severe and persistent rather than the mild tiredness common in early GLP-1 treatment
- Any thoughts of self-harm, suicide, or a desire to not be alive
None of these symptoms should be dismissed as expected side effects of GLP-1 treatment. If you are experiencing them, speak with your prescribing physician promptly. Do not discontinue a GLP-1 medication without medical guidance, as abrupt discontinuation can affect glucose control and other health parameters, but do communicate your symptoms clearly so that your care team can make an informed assessment.
If you are experiencing thoughts of suicide or self-harm, do not wait for your next scheduled appointment. Call or text 988 to reach the Suicide and Crisis Lifeline. Text HOME to 741741 for the Crisis Text Line. If you are in immediate danger, call 911 or go to your nearest emergency department.
Should Patients With Pre-Existing Depression Avoid GLP-1 Drugs?
There is currently no FDA warning that prohibits or restricts the use of GLP-1 medications in patients with a history of depression or other psychiatric conditions. The available evidence does not show that semaglutide or other GLP-1 drugs consistently worsen depression in this population. Some studies, as noted above, have found lower rates of depression among GLP-1 users overall, which may reflect secondary benefit from metabolic and weight-related improvements.
That said, patients with pre-existing depression, anxiety, or a history of suicidal ideation are a population in which baseline psychiatric risk is elevated, and who are therefore more likely to experience psychiatric events during any treatment — whether or not those events are related to the medication. For this group, more frequent mental health monitoring during GLP-1 treatment is clinically reasonable, and the decision to start or continue GLP-1 therapy should be made in full consultation with both the prescribing physician and any mental health providers involved in the patient’s care. The risks and benefits of treatment, including any potential psychiatric considerations, should be part of that discussion.
Psychiatric Effects and the GLP-1 Litigation Landscape
The current landscape of GLP-1 personal injury litigation is focused primarily on serious gastrointestinal injuries — gastroparesis, bowel obstruction, ileus, and pancreatitis — and on NAION vision loss. These are the injury categories that underpin the vast majority of the more than 3,600 cases currently pending in MDL 3094 and the growing NAION claims in MDL 3163. Psychiatric claims are not currently a primary driver of either MDL.
However, the FDA warning letter issued to Novo Nordisk in March 2026 — which cited a suicide-related adverse event among the reports the company allegedly failed to submit within the required 15-day window — has drawn renewed attention to the intersection of psychiatric adverse events and GLP-1 regulatory compliance. If future research were to establish a causal link between GLP-1 drugs and psychiatric harm, the failure-to-warn framework that underlies the existing litigation would provide a ready legal vehicle for psychiatric injury claims. For current status on the MDL proceedings, see our GLP-1 litigation status page.
Key Takeaways
For patients, caregivers, and clinicians navigating the questions around GLP-1 drugs and mental health, the following points represent the current state of the evidence:
- No causal link between GLP-1 drugs and depression, suicidal ideation, or other psychiatric harm has been established by the FDA, the EMA, or the peer-reviewed literature as of May 2026
- Both the FDA (January 2026) and the EMA (2023) conducted formal reviews of the available psychiatric safety data and reached the same conclusion: no confirmed causal association
- Some studies using adverse event database analyses have identified reporting signals for suicidal ideation in GLP-1 users; other large population studies have found lower rates of depression and anxiety in GLP-1 users compared to comparator groups
- The research is difficult to interpret because of confounding by the baseline psychiatric burden of the underlying conditions being treated, and because GLP-1 drugs produce multiple downstream effects — weight loss, metabolic improvement, altered reward processing — that independently influence mood
- GLP-1 receptors are expressed in brain regions involved in mood, reward, and appetite regulation, meaning the biological plausibility of mood-related effects — beneficial or harmful — is not zero
- Patients experiencing new or worsening depression, anxiety, or any thoughts of self-harm during GLP-1 treatment should contact their healthcare provider promptly and should seek emergency care if in crisis
- Psychiatric claims are not currently the primary focus of GLP-1 litigation, but the broader regulatory surveillance environment — including the March 2026 FDA warning letter to Novo Nordisk — keeps this question in active consideration
The honest answer to whether Ozempic can cause depression or suicidal thoughts is: we do not know with certainty, and the current best evidence suggests the risk, if it exists, is not large enough to have been detected in two major regulatory reviews or in many large population studies. That answer may evolve as longer-term data accumulates and as the patient population using these drugs continues to grow and diversify. In the meantime, careful monitoring and open communication between patients and their care teams remains the most appropriate clinical response to the uncertainty that remains.